Abstract
You have accessJournal of UrologyKidney Cancer: Localized: Active Surveillance1 Apr 2017PD59-06 QUALITY OF LIFE SCORES IN PATIENTS WITH SMALL RENAL MASSES WHO HAVE UNDERGONE RENAL MASS BIOPSY COMPARED TO THOSE WHO HAVE NOT: ANALYSIS OF THE DISSRM REGISTRY. Alice Semerjian, Ridwan Alam, Hiten Patel, Mark Riffon, Michael Johnson, Peter Chang, Andrew Wagner, James McKiernan, Bruce Trock, Mohamad Allaf, and Phillip Pierorazio Alice SemerjianAlice Semerjian More articles by this author , Ridwan AlamRidwan Alam More articles by this author , Hiten PatelHiten Patel More articles by this author , Mark RiffonMark Riffon More articles by this author , Michael JohnsonMichael Johnson More articles by this author , Peter ChangPeter Chang More articles by this author , Andrew WagnerAndrew Wagner More articles by this author , James McKiernanJames McKiernan More articles by this author , Bruce TrockBruce Trock More articles by this author , Mohamad AllafMohamad Allaf More articles by this author , and Phillip PierorazioPhillip Pierorazio More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2634AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Renal mass biopsy (RMB) can be employed as an adjunct to the decision-making process for patients with small renal masses. It is hypothesized that the pathological diagnosis provided by RMB purports a QOL advantage by alleviating cancer-related uncertainty and anxiety. This study evaluates the influence of RMB on QOL in a large prospective registry of patients with SRM. METHODS The DISSRM (Delayed Intervention and Surveillance for Small Renal Masses) Registry is a multi-institutional study that prospectively follows patients with SRM who elect primary intervention (PI) or active surveillance (AS). Patients complete SF12 QOL questionnaire at enrollment, 6 and 12 months, and subsequently on an annual basis. SF12 scores, MCS (Mental Component Summary) and PCS (Physical Component Summary) were compared between patients who had RMB versus those who did not in the PI, AS, and crossover groups separately using ANOVA and linear regression mixed modeling. RESULTS 619 patients were identified in the DISSRM Registry, of whom 320 were in the AS arm and 299 in the PI arm. 84 patients (13.6%) underwent biopsy, 34 (40.6%) in the PI group, 35 (41.6%) in the AS group, and 15 (17.8%) in the AS group who crossed over. Median age, ECOG performance status and Charlson comorbidity Index (CCI) were similar regardless of biopsy status among the AS and PI groups. In PI patients, there were no significant differences between SF12, MCS or PCS (p>0.092) or changes in SF12, MCS, or PCS (p>0.162) in patients who underwent biopsy and those who did not across all time points up to 84 months. In the AS patients who did not crossover, no differences in SF12, MCS and PCS were seen between patients who had biopsy and those who did not (p>0.0564). PCS declined over time in patients who stayed on AS without biopsy (p<0.001), but all other measures were unchanged over time (p>0.7291). In the crossover group, SF12, MCS, and PCS were lower at 24 and 48 months in patients who had not undergone biopsy (p=0.002). These patients were older (72.5 vs 67.2, p=0.003), had higher CCI (p=0.004), and lower ECOG performance status (p=0.045). There were no changes to SF12, MCS, or PCS scores in crossover patients regardless of biopsy status over time (p>0.1513). CONCLUSIONS AS and PI patients who underwent RMB during follow-up in DISSRM did not have significant changes in quality of life scores over time, nor did they have worse scores than their counterparts who did not undergo biopsy. A pathological diagnosis through RMB did not appear to have a beneficial or detrimental effect on QOL while on AS. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1135 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Alice Semerjian More articles by this author Ridwan Alam More articles by this author Hiten Patel More articles by this author Mark Riffon More articles by this author Michael Johnson More articles by this author Peter Chang More articles by this author Andrew Wagner More articles by this author James McKiernan More articles by this author Bruce Trock More articles by this author Mohamad Allaf More articles by this author Phillip Pierorazio More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.